Case Report

Acute-onset paraneoplastic cerebellar degeneration secondary to neuroendocrine carcinoma with atypical prognosis: a case report

Kunyu Wang1,*, Yan Miao1,*, Haoyong Ning2, Feng Guo3, Yang Bian1, Qingqing Wang1, Chenjing Sun1, Xiaokun Qi1 and Feng Qiu1

Abstract
Paraneoplastic cerebellar degeneration (PCD) is a neurological syndrome that is likely caused by tumor-induced autoimmunity against the cerebellum. Neuroendocrine carcinoma (NEC) is a type of neoplasm with high-grade malignant histology and biological behavior. The prognosis for both PCD and NEC is typically poor. We report a case of PCD secondary to metastatic NEC in the lymph nodes, with an unknown primary origin. The case presented acute cerebellar manifestations with typical neuroimaging findings, but with atypical prognosis after lymph node dissection. Neurological symptoms can provide clues to potential tumors, and early antitumor treatment may have contributed to the positive prognosis of PCD secondary to NEC in the present case.

Keywords
Paraneoplastic neurological syndromes, paraneoplastic cerebellar degeneration, neuroendocrine carcinoma, acute cerebellar manifestation, metastasis, tumor

Date received: 16 July 2020; accepted: 13 January 2021

1Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China
2Department of Pathology, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China
3Department of Nuclear Medicine, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China

*These authors contributed equally to this work.

Corresponding author:
Feng Qiu, Department of Neurology, Sixth Medical Center of Chinese PLA General Hospital, 6 Fucheng Road, Haidian District, Beijing 100048, China.
Email: qiufengnet@hotmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction

Paraneoplastic neurological syndromes (PNSs) are a heterogeneous group of neurological disorders that are likely caused by tumor-associated autoimmune responses. Paraneoplastic cerebellar degeneration (PCD), which is one of the most common PNSs, begins subacutely and occurs because of autoimmune damage to the cerebellum. Neuroendocrine carcinoma (NEC) is a type of highly aggressive malignant carcinoma. It has an active proliferative capacity and expresses neuroendocrine markers, such as synaptophysin and chromogranin A. The prognosis for patients with NEC is extremely poor. In this case report, we present a rare patient with PCD secondary to NEC with acute-onset cerebellar manifestations and a good prognosis.

Case presentation

A 48-year-old man with no medical history presented to our hospital in March 2013 with acute onset of progressive cerebellar ataxia and dizziness, which had started approximately 80 days earlier. He reported dysarthria and difficulty with ambulation. He was unable to walk without assistance on admission. He also reported an 18-day history of dysphagia and a weight loss of 5 kg from symptom onset.

The patient denied a family history of similar diseases. Physical examination revealed a severe cerebellar syndrome, including dysarthric speech, unsteady gait, bilateral vertical nystagmus, bilateral finger-to-nose and heel–knee–tibia dysmetria, bilateral dysdiadochokinesia, and a positive Romberg sign. Neither muscle weakness nor sensory damage was detected except for unilateral weakness of the soft palate. Deep tendon reflexes were normal in the upper and lower limbs. In addition, two palpable, enlarged lymph nodes measuring about 2.5 cm in diameter had been present in the right submandibular area for approximately 2 years. Based on the clinical manifestations, a diagnosis of PCD was probable, although further exclusions were required for diagnoses such as Miller Fisher syndrome, glutamic acid decarboxylase 65 (GAD65) antibody-related cerebellar ataxia, multiple sclerosis, stroke, and ataxia with vitamin E deficiency.

The results of a routine blood test, biochemical examination, and tumor biomarkers were generally unremarkable, except that the patient’s neuron-specific enolase was 12.8 ng/mL (normal values: 0–12.5 ng/mL). A lumbar puncture was performed, and cerebrospinal fluid (CSF) analysis revealed a normal leukocyte count, a protein level of 1144 mg/L (normal: 150–450 mg/L), and negative oligoclonal bands. Onconeural antibodies, including anti-Hu, anti-Yo, anti-Ri, anti-Ma2, anti-crossveinless-2 (CV2), anti-amphiphysin, anti-Tr, anti-ZIC4, anti-sex determining region Y-box 1 (SOX1), anti-recoverin, anti-titin, and anti-GAD65, were measured by immunoblotting and were not present in the serum or CSF. Brain magnetic resonance imaging (MRI) displayed marked cerebellar atrophy (Figure 1).

Figure 1. Brain magnetic resonance T2-weighted imaging showing marked cerebellar atrophy (arrow).
Electroencephalography, electromyography, nerve conduction velocities, chest computed tomography (CT), and thyroid ultrasonography were normal. A positron emission tomography/computed tomography (PET/CT) scan showed that the atrophic cerebellum had diffusely reduced 18F-fluorodeoxyglucose (FDG) metabolism, and that the two enlarged right submandibular lymph nodes had abnormally high 18F-FDG metabolism (Figure 2). The patient then underwent an ultrasound-guided biopsy of the enlarged lymph nodes, and the pathological diagnosis was metastatic NEC with a high proliferation rate (Ki-67 index > 90%) (Figure 3). To find the origin of the metastasis, a bronchoscopy, nasal endoscopy, gastroscopy, and colonoscopy were all performed, but no primary tumor was identified. Based on these findings, the patient was diagnosed with PCD secondary to NEC.

The patient then underwent a radical right neck dissection, and pathological examination via cryosection was performed. Of 32 cervical and one submandibular lymph nodes, two cervical lymph nodes were positive for metastatic NEC (Ki-67 > 90%); these lymph nodes were removed. The patient’s neurological symptoms were gradually relieved within 1 week after the operation. The patient was discharged with mild dizziness and dysarthria. At discharge, he was able to walk very slowly unassisted, and his symptoms of dysphagia and nystagmus had disappeared. Over a follow-up period of 7 years without further treatment, a brain MRI, chest CT, and abdomen CT were performed every 6 months. No indication of a tumor was
found, and the patient’s neurological symptoms did not progress.

**Discussion**

PCD is an uncommon neurological syndrome that results from tumor-induced autoimmunity against the cerebellum. It is characterized clinically by progressive cerebellar deficits with a subacute onset, with symptoms and signs that include dizziness, ataxic gait, dysarthria, and nystagmus, which present over several weeks. In addition, symptoms of dysphagia, diplopia, and cognitive and psychiatric morbidity have also been noted. The proportion of patients with acute onset—as occurred in our patient—is small, occurring in 8.3% of patients according to a recent retrospective analysis. Early on, brain MRI in PCD is usually unremarkable, with later stages showing cerebellar atrophy. An 18F-FDG PET/CT scan shows a reduced mean metabolic rate in the cerebellum. Onconeuronal antibodies in either the serum or CSF are significant indicators of tumors and primary tumor-related sites. However, an absence of antibodies is not sufficient to rule out PCD. In the present case, based on the typical clinical manifestations consistent with PCD and tumor and the typical neuroimaging results, a diagnosis of PCD was suspected immediately. The pathological biopsy from the enlarged submandibular lymph nodes indicated metastatic NEC. We therefore diagnosed definite PCD according to the diagnostic criteria for PNSs, established in 2004.

The gastrointestinal tract, pancreas, and lungs are the most frequent sites of NEC, but the primary origins are unknown in 41.3% of patients with NEC.
In addition, although PCD can be secondary to any cancer, the vast majority of cases result from gynecological or breast cancers, small cell lung cancer, or Hodgkin’s disease. Based on the drainage area of the submandibular lymph nodes, the typical sites of NEC, and the common cancers to which PCD is secondary, endoscopies for related organs were performed for this patient. However, no tumor was identified.

No evidence-based guidelines are currently available for the treatment of PCD because of its extremely low prevalence. Three major therapies have been used clinically: modulation of autoimmunity by immunosuppression (corticosteroids) or intravenous immunoglobulin G; removal of antibodies by plasma exchange; or antitumor therapy via surgery or chemotherapy. One study has suggested that antitumor therapy is the only successful approach for improving neurological outcomes in patients with PNSs. Recently, both a case of PCD and a case of autoimmune encephalitis have been reported with remarkable and unexpected improvement following antitumor treatment. In the present case, although the primary origin of the metastasis was not identified, a radical right neck dissection surgery was performed based on the limited literature, the advice of otorhinolaryngology head and neck surgeons, and our own experience. The neurological symptoms of our patient were alleviated after the surgery. The mechanism of the therapeutic effect may be that removal of the antigenic stimulus by surgery resulted in the cessation or reduction of the damaging autoimmune attack against the cerebellum.

Neuroendocrine neoplasms are divided into well-differentiated neuroendocrine tumors and NEC with high-grade malignant histology and biological behavior. The mean survival of NEC is 1.2 years. It was therefore unexpected that our patient remained alive, without a worsening of his neurological symptoms, during 7 years of follow-up. With early diffuse neuronal loss in the cerebellum, a late improvement in symptoms is rare. To the best of our knowledge, no cases of PCD secondary to NEC with a better prognosis or longer follow-up time than our patient have been previously reported. Acute onset and a rapid improvement of symptoms after lymph node dissection are not conventional characteristics of PCD. It is therefore important to elucidate atypical presentations. Good performance status, normal levels of platelets and lactate dehydrogenase, and antitumor surgery without delay may be factors that contributed to the positive outcome in our patient. We continue to follow the patient closely.

In summary, this report presents a case of PCD secondary to NEC with a good prognosis and an extended follow-up. This case study indicates that special attention should be paid to patients’ neurological symptoms because they may suggest the existence of potential tumors.

Ethics statement

This report was approved by the Ethics Committee of Sixth Medical Center of Chinese PLA General Hospital, and the patient has provided informed consent.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This study was supported by the New Technology and New Business Fund (No. HZXJS[2018]-10).

ORCID iDs

Yang Bian https://orcid.org/0000-0002-4002-5646
Feng Qiu https://orcid.org/0000-0001-6931-1219
References
1. Leyboldt F and Wandinger KP. Paraneoplastic neurological syndromes. Clin Exp Immunol 2014; 175: 336–348.
2. Giometto B, Grisold W, Vitaliani R, et al. Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 2010; 67: 330–335.
3. Vogrig A, Gigli GL, Segatti S, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol 2020; 267: 26–35.
4. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 2018; 31: 1770–1786.
5. Zandee WT, Van Der Zwan JM, De Herder WW, et al. Importance of complete pathology reporting for neuroendocrine carcinoma: WHO guidelines are a good start but not enough. Neuroendocrinology 2020; 110: 994–1000.
6. Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55: 713–715.
7. Venkatraman A and Opal P. Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review. Ann Clin Transl Neurol 2016; 3: 655–663.
8. Shams’ili S, Grefkens J, De Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409–1418.
9. Key RG and Root JC. Anti-Yo mediated paraneoplastic cerebellar degeneration in the context of breast cancer: a case report and literature review. Psychooncology 2013; 22: 2152–2155.
10. Vogrig A, Bernardini A, Gigli GL, et al. Stroke-like presentation of paraneoplastic cerebellar degeneration: a single-center experience and review of the literature. Cerebellum 2019; 18: 976–982.
11. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135–1140.
12. Walter T, Tougeron D, Baudin E, et al. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort. Eur J Cancer 2017; 79: 158–165.
13. Greenlee JE. Treatment of paraneoplastic cerebellar degeneration. Curr Treat Options Neurol 2013; 15: 185–200.
14. Mirallas O, Rezqallah Arón MA, Saoudi Gonzalez N, et al. Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer. BMJ Case Rep 2020; 13: e233863.
15. Martin AN, Dillon PM, Jones DE, et al. Anti-Yo mediated paraneoplastic cerebellar degeneration associated with pseudobulbar affect in a patient with breast cancer. Case Rep Oncol Med 2017; 2017: 812069.
16. Candler PM, Hart PE, Barnett M, et al. A follow up study of patients with paraneoplastic neurological disease in the United Kingdom. J Neurol Neurosurg Psychiatry 2004; 75: 1411–1415.
17. Simard C, Vogrig A, Joubert B, et al. Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies. Neurol Neuroimmunol Neuroinflamm 2020; 7: e699.
18. Vogrig A, Pauletto G, Belgrado E, et al. Effect of thymectomy on refractory autoimmune status epilepticus. J Neuroimmunol 2018; 317: 90–94.
19. Kumari VA, Gupta P, Srivastava MV, et al. Paraneoplastic cerebellar degeneration as the first evidence of malignancy: a case report. J Obstet Gynaecol Res 2014; 40: 1463–1465.
20. Takasugi J, Shimamura M, Koda T, et al. Paraneoplastic cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with neuroendocrine carcinoma of the oropharynx. Intern Med 2018; 57: 587–590.
21. Sorbye H, Welin S, Langer SW, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24: 152–160.